

BioMed Realty Trust Inc  
Form 8-K  
March 29, 2011

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of  
the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 23, 2011**

**BioMed Realty Trust, Inc.**

**BioMed Realty, L.P.**

(Exact name of registrant as specified in its charter)

**Maryland**

**1-32261 (BioMed Realty Trust,  
Inc.)  
000-54089 (BioMed Realty, L.P.)**

**20-1142292 (BioMed Realty  
Trust, Inc.)  
20-1320636 (BioMed Realty,  
L.P.)**

(State or Other  
Jurisdiction of  
Incorporation)

(Commission File No.)

(I.R.S. Employer  
Identification No.)

**17190 Bernardo Center Drive  
San Diego, California 92128**

(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: **(858) 485-9840**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events.**

On March 23, 2011, BioMed Realty Trust, Inc. (the Company ) and BioMed Realty, L.P. (the Operating Partnership ) entered into an underwriting agreement with Wells Fargo Securities, LLC, KeyBanc Capital Markets Inc. and Morgan Stanley & Co. Incorporated, as representatives of the underwriters named therein (the Underwriters ), pursuant to which the Operating Partnership agreed to issue and sell \$400,000,000 aggregate principal amount of its 3.85% Senior Notes due 2016 (the Notes ). The Notes will be fully and unconditionally guaranteed by the Company.

The Operating Partnership intends to use the net proceeds of the Notes offering to repay a portion of the outstanding indebtedness under its \$720.0 million unsecured line of credit and for other general corporate and working capital purposes.

**Item 9.01 Financial Statements and Exhibits.**

(d) The following exhibit is filed herewith:

**Exhibit**

**Number**

**Description of Exhibit**

|     |                                                                                                                                                                                                                                               |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 1.1 | Underwriting Agreement, dated as of March 23, 2011, among the Company, the Operating Partnership and Wells Fargo Securities, LLC, KeyBanc Capital Markets Inc. and Morgan Stanley & Co. Incorporated, as representatives of the Underwriters. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned hereunto duly authorized.

Date: March 29, 2011

BIOMED REALTY TRUST, INC.

By: /s/ GREG N. LUBUSHKIN  
Name: Greg N. Lubushkin  
Title: Chief Financial Officer

BIOMED REALTY, L.P.

By: BioMed Realty Trust, Inc.  
its General Partner

By: /s/ GREG N. LUBUSHKIN  
Name: Greg N. Lubushkin  
Title: Chief Financial Officer